Literature DB >> 24581758

Personalized medicine for breast cancer: it is a new day!

Christy A Russell1.   

Abstract

Breast cancer remains the most common cancer diagnosed in women in the United States and is second only to lung cancer as a cause of cancer mortality. Breast cancer has become the prototypical solid tumor where targets have been identified within the tumor allowing for a personalized approach of systemic therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Estrogen receptor; HER2 positive breast cancer; Personalized medicine; Triple negative breast cancer

Mesh:

Substances:

Year:  2013        PMID: 24581758     DOI: 10.1016/j.amjsurg.2013.10.016

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Improvement of cytotoxicity and necrosis activity of ganoderic acid a through the development of PMBN-A.Her2-GA as a targeted nano system.

Authors:  P Motamed Fath; M Rahimnejad; S Moradi-Kalbolandi; B Ebrahimi Hosseinzadeh; T Jamshidnejad-Tosaramandani
Journal:  RSC Adv       Date:  2022-01-05       Impact factor: 3.361

2.  Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression.

Authors:  Harald Hessel; Manuela Poignée-Heger; Sabine Lohmann; Bianca Hirscher; Andrea Herold; Gerald Assmann; Jan Budczies; Karl Sotlar; Thomas Kirchner
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.